[PDF][PDF] Tumor necrosis factor α as a new target for renal cell carcinoma: two sequential phase II trials of infliximab at standard and high dose
ML Harrison, E Obermueller, NR Maisey… - Journal of Clinical …, 2007 - academia.edu
ML Harrison, E Obermueller, NR Maisey, S Hoare, K Edmonds, NF Li, D Chao, K Hall, C Lee…
Journal of Clinical Oncology, 2007•academia.eduTumor Necrosis Factor α As a New Target for Renal Cell Carcinoma: Two Sequential Phase II
Trials of Infliximab at Standard and Page 1 Tumor Necrosis Factor α As a New Target for
Renal Cell Carcinoma: Two Sequential Phase II Trials of Infliximab at Standard and High Dose
Michelle L. Harrison, Eva Obermueller, Nick R. Maisey, Susan Hoare, Kim Edmonds, Ningfeng
F. Li, David Chao, Kate Hall, Chooi Lee, Eleni Timotheadou, Kellie Charles, Roger Ahern, D.
Mike King, Tim Eisen, Robert Corringham, Mark DeWitte, Frances Balkwill, and Martin Gore A …
Trials of Infliximab at Standard and Page 1 Tumor Necrosis Factor α As a New Target for
Renal Cell Carcinoma: Two Sequential Phase II Trials of Infliximab at Standard and High Dose
Michelle L. Harrison, Eva Obermueller, Nick R. Maisey, Susan Hoare, Kim Edmonds, Ningfeng
F. Li, David Chao, Kate Hall, Chooi Lee, Eleni Timotheadou, Kellie Charles, Roger Ahern, D.
Mike King, Tim Eisen, Robert Corringham, Mark DeWitte, Frances Balkwill, and Martin Gore A …
Purpose
Tumor necrosis factor α (TNF-α) may play a role in renal cell carcinoma (RCC). We performed two sequential phase II studies of infliximab, an anti–TNF-α monoclonal antibody, in patients with immunotherapy-resistant or refractory RCC.
academia.edu